403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Biovaxys Technology Corp
(MENAFN- Baystreet) 11:20 AM EST - BioVaxys Technology Corp : Announces that results from a collaborative research project conducted in the Bavarian Forest National Park in Germany have recently been published in the European Journal of Wildlife Research. BioVaxys Licensee SpayVac-for-Wildlife, Inc., reports further positive single-dose efficacy data for its immunocontraceptive vaccine and initiation of regulatory submission process. BioVaxys Technology Corp.
shares C are trading unchanged at $0.27.
Full Press Release:
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Casper Network Advances Regulated Tokenization With ERC-3643 Standard
- Forex Expo Dubai Wins Guinness World Recordstm With 20,021 Visitors
- Superiorstar Prosperity Group Russell Hawthorne Highlights New Machine Learning Risk Framework
- Freedom Holding Corp. (FRHC) Shares Included In The Motley Fool's TMF Moneyball Portfolio
- Versus Trade Launches Master IB Program: Multi-Tier Commission Structure
- Ozzy Tyres Grows Their Monsta Terrain Gripper Tyres Performing In Australian Summers
More Story
Comments
No comment